

# Olubukola M Abiona

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3709936/olubukola-m-abiona-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

7,061  
citations

14  
h-index

20  
g-index

20  
ext. papers

9,487  
ext. citations

24.3  
avg, IF

6.81  
L-index

#	Paper	IF	Citations
20	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 772864	8.4	4
19	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , <b>2021</b> , 37, 109929	10.6	18
18	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	169
17	Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates <b>2021</b> ,		24
16	SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques <b>2021</b> ,		1
15	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. <i>Science Immunology</i> , <b>2021</b> , 6,	28	12
14	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373,	33.3	80
13	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	13
12	Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants <b>2021</b> ,		13
11	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , <b>2021</b> , 54, 1869-1882.e6	32.3	16
10	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , <b>2021</b> , 373, eabj0299	33.3	86
9	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. <i>Science</i> , <b>2020</b> , 367, 1260-1263	33.3	5176
8	Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance <b>2020</b> ,		39
7	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness <b>2020</b> ,		62
6	A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone <b>2020</b> ,		2
5	LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection <b>2020</b> ,		64
4	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , <b>2020</b> , 586, 567-571	50.4	594

3	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , <b>2020</b> , 33, 108322	10.6	35
2	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1544-1555	59.2	612
1	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. <i>Scientific Reports</i> , <b>2020</b> , 10, 18149	4.9	41